Molecular Monitoring of Chronic Myelogenous Leukemia: Identification of the Most Suitable Internal Control Gene for Real-Time Quantification of BCR-ABL Transcripts
- 31 May 2006
- journal article
- Published by Elsevier BV in The Journal of Molecular Diagnostics
- Vol. 8 (2), 231-239
- https://doi.org/10.2353/jmoldx.2006.040404
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- β-Glucuronidase Is an Optimal Normalization Control Gene for Molecular Monitoring of Chronic Myelogenous LeukemiaThe Journal of Molecular Diagnostics, 2006
- Discontinuation of imatinib therapy after achieving a molecular responseBlood, 2004
- Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaBlood, 2004
- Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remissionLeukemia, 2003
- Comprehensive Validation of a Real-Time Quantitative bcr-abl Assay for Clinical Laboratory UseAmerican Journal of Clinical Pathology, 2003
- Quantitative real‐time reverse‐transcription polymerase chain reaction for diagnosis of BCR‐ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantationEuropean Journal of Haematology, 2003
- Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 casesLeukemia, 2002
- Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBritish Journal of Haematology, 1999
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assayLeukemia, 1999